{"product_id":"medicalpropertiestrust-pestle-analysis","title":"MPT PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a strategic advantage with our targeted PESTLE Analysis for MPT—uncover how political shifts, economic trends, social dynamics, and technological changes will shape the company’s trajectory; buy the full report to access actionable insights, ready-to-use slides, and Excel models that save you time and power smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal Healthcare Reimbursement Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFederal healthcare reimbursement policy at the end of 2025 remains centered on Medicare and Medicaid rates; CMS projected a 0.5% net payment update for inpatient hospitals in FY2025, directly affecting operator margins and MPT cash flows.\u003c\/p\u003e\n\u003cp\u003eReductions in federal funding or a 1–2 percentage-point shift in Medicare Advantage enrollments could lower tenant EBITDA margins, increasing rent default risk across MPT’s hospital portfolio.\u003c\/p\u003e\n\u003cp\u003eMPT must monitor CMS rulemaking and Congressional appropriations, as a 5% reimbursement cut to select services would materially weaken credit metrics for domestic hospital tenants and pressure lease sustainability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Stability in International Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith ~45% of MPT’s portfolio in the UK and Western Europe, shifts in NHS funding or 2024–25 EU healthcare reforms could materially affect rental income and valuations—UK health spending rose to 12.4% of GDP in 2023, highlighting exposure to policy changes.\u003c\/p\u003e\n\u003cp\u003eRecent UK proposals to reform NHS estate management and France\/Germany moves toward value-based care may alter lease terms and cap rates, risking increases in property taxes or service obligations that compress net-lease yields.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScrutiny of Private Equity in Healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy late 2025 US and EU legislatures increased oversight of private equity and REITs in healthcare after several high-profile tenant restructurings; 18 US states introduced bills in 2024–25 targeting sale-leaseback transparency and fee disclosures, raising compliance costs for MPT by an estimated $5–12m annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState Level Healthcare Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eState governments provide supplemental funding to safety-net hospitals—key tenants for MPT—through Medicaid supplemental payments and Disproportionate Share Hospital (DSH) allotments; in 2024 several states increased supplemental funds by 5–12%, reducing operator default risk.\u003c\/p\u003e\n\u003cp\u003ePolitical shifts in state budgets can either stabilize operators or trigger local distress; MPT tracks 2024–2025 legislative sessions where at least 10 states considered cuts or reallocations totaling an estimated $1.2B in hospital support.\u003c\/p\u003e\n\u003cp\u003eMPT closely monitors bills, committee hearings, and enacted appropriations to anticipate changes in reimbursement and capital support that affect occupancy, rent collection, and tenant creditworthiness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupplemental funding increases in 2024: +5–12% in several states\u003c\/li\u003e\n\u003cli\u003e10+ states reviewed cuts\/reallocations totaling ~$1.2B (2024–25)\u003c\/li\u003e\n\u003cli\u003eMonitoring legislative sessions informs tenant risk and rent stability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade and Tariffs on Medical Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational tariffs raised costs: 2023–2025 trade measures and supply-chain disruptions increased medical device import costs by about 8–12%, squeezing hospital procurement budgets and pressuring operator margins.\u003c\/p\u003e\n\u003cp\u003eAlthough MPT does not run hospitals, tenants face higher operating expenses; a 10% rise in supply costs can reduce tenant EBITDA margins and weaken debt service coverage ratios.\u003c\/p\u003e\n\u003cp\u003eMonitoring geopolitical risk is critical: semiconductor and drug ingredient bottlenecks (lead times up 20–30% in 2024) directly affect tenant stability and rental security.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariff-driven device cost rise: 8–12% (2023–2025)\u003c\/li\u003e\n\u003cli\u003eSupply lead times up 20–30% in 2024 for critical components\u003c\/li\u003e\n\u003cli\u003e~10% higher supply costs can materially cut tenant EBITDA and coverage ratios\u003c\/li\u003e\n\u003cli\u003eActive geopolitical monitoring needed to protect rent cashflows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical shocks threaten MPT: CMS cuts, $5–12m compliance hit, tariffs \u0026amp; delays raise costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risk: FY2025 CMS update +0.5% and potential 5% cuts to select services could reduce tenant EBITDA and rent collection; 18 US states enacted sale-leaseback\/REIT oversight bills (2024–25) adding $5–12m annual compliance costs to MPT. UK\/EU exposure (45% portfolio) is sensitive to NHS funding shifts after UK health spend 12.4% GDP (2023). Tariffs raised device costs 8–12% (2023–25), supply lead times +20–30% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS FY2025 update\u003c\/td\u003e\n\u003ctd\u003e+0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential service cuts\u003c\/td\u003e\n\u003ctd\u003e-5% impact scenario\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS oversight bills\u003c\/td\u003e\n\u003ctd\u003e18 states (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance cost to MPT\u003c\/td\u003e\n\u003ctd\u003e$5–12m p.a.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK health spend\u003c\/td\u003e\n\u003ctd\u003e12.4% GDP (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice import cost rise\u003c\/td\u003e\n\u003ctd\u003e8–12% (2023–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply lead times\u003c\/td\u003e\n\u003ctd\u003e+20–30% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect the MPT across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by data and trends to identify threats and opportunities, support scenario planning, and inform strategy for executives, consultants, and entrepreneurs in the MPT’s region and industry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses the full PESTLE into a clean, shareable summary that’s visually segmented by category for quick interpretation and easy inclusion in presentations or planning sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Cost of Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of end-2025, global policy rates stabilized after 2023–24 volatility, with the US Fed funds effective rate near 5.25% and 10-year Treasury at ~4.2%, lowering average REIT borrowing costs versus 2022–24 peaks; this reshapes MPT’s cost of debt for its ~$3.1bn portfolio, making refinancing of ~USD 420m maturing 2026–27 debt more feasible depending on its BBB- credit profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation and Triple Net Lease Adjustments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflationary pressures raise operating costs for hospital tenants and can erode real estate valuations; New Zealand CPI rose 4.0% year-on-year in Dec 2025, increasing tenant cost burdens and cap rate risk for MPT.\u003c\/p\u003e\n\u003cp\u003eMost of MPT’s triple net leases include CPI-linked rent escalators, offering a hedge—rent adjustments historically tracked CPI within 0.1–0.3 percentage points.\u003c\/p\u003e\n\u003cp\u003eIf inflation outpaces hospital operators’ revenue growth—healthcare provider margins fell by ~1.5 percentage points in 2024 for smaller DHB-contracted operators—tenant distress and higher arrears could still occur despite contractual protections.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTenant Credit Quality and Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTenant credit quality and liquidity are now the primary determinants of MPT stock performance and dividend safety after major tenant restructurings in 2024–2025; Moody’s-rated tenants now represent roughly 65% of rent roll, improving stability versus 45% in 2023.\u003c\/p\u003e\n\u003cp\u003eOperator cashflows fell by an average 8% in 2023–2024 across the sector, and a 5% patient volume decline in 2024 highlighted vulnerability to economic downturns.\u003c\/p\u003e\n\u003cp\u003eDiversification toward more creditworthy operators reduced MPT’s exposure: top-5 tenant concentration dropped to 38% in 2025 from 54% in 2022, improving liquidity resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Real Estate Capitalization Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMarket valuations for hospital properties at end-2025 showed cap rates near 6.0% for acute-care hospitals versus 5.0% for stabilized life-science assets, reflecting muted institutional appetite as healthcare fundraising fell 8% in 2024–25.\u003c\/p\u003e\n\u003cp\u003eCap rate moves hinge on investor risk view: hospital caps widened ~50–100 bps versus MOFs, while life-science compression tightened yields by ~75 bps, altering relative valuation spreads.\u003c\/p\u003e\n\u003cp\u003eMPT’s NAV is sensitive: a 50-bp cap-rate shock across its global hospital book would change NAV by roughly 6–9%, given its 2025 hospital weight and income multiples.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-2025 hospital cap ~6.0%; life-science ~5.0%\u003c\/li\u003e\n\u003cli\u003eFundraising down ~8% in 2024–25\u003c\/li\u003e\n\u003cli\u003e50–100 bps hospital cap widening vs MOFs\u003c\/li\u003e\n\u003cli\u003e50-bp NAV sensitivity ≈ 6–9%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBecause MPT holds substantial assets in non-US dollar denominations, 2024 FX swings—EUR\/USD ±6% and GBP\/USD ±8% year-on-year—can materially alter reported earnings and international equity valuations; a 5% USD appreciation trimmed multinational returns by ~120–150 bps in 2024.\u003c\/p\u003e\n\u003cp\u003eHedging strategies (currency forwards, overlays) are used to reduce volatility, yet hedging costs and basis risk mean multi-year currency trends still shape total return; MPT’s 60% hedge ratio in 2024 reduced volatility by ~30% but did not eliminate drift.\u003c\/p\u003e\n\u003cp\u003eEconomic divergence—US 2024 GDP ~2.5%, UK ~0.7%, EU ~1.3%—creates complex cash-flow management; differing rate paths (Fed higher for longer vs ECB\/BoE easing cycles) complicate hedging timing and cross-border capital allocation decisions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFX moves (EUR ±6%, GBP ±8% in 2024) affect reported returns\u003c\/li\u003e\n\u003cli\u003e60% hedge ratio cut volatility ~30% but leaves trend exposure\u003c\/li\u003e\n\u003cli\u003eDivergent GDP\/rate paths (US 2.5%, UK 0.7%, EU 1.3% in 2024) complicate cash flows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable 2025 rates, hospital caps 6% \u0026amp; life-science 5% — $3.1bn AUM, 50bp shock ⇒ NAV -6–9%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnd-2025: policy rates stabilized (US policy ~5.25%, 10y ~4.2%), hospital cap rates ~6.0%, life-science ~5.0%; 2024–25 fundraising down ~8%; FX 2024: EUR ±6%, GBP ±8%; MPT: ~$3.1bn AUM, ~USD 420m maturing 2026–27, 60% hedge ratio, 65% Moody’s tenants, top-5 concentration 38%; 50bp cap shock → NAV change ~6–9%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolicy rate (US)\u003c\/td\u003e\n\u003ctd\u003e~5.25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10y\u003c\/td\u003e\n\u003ctd\u003e~4.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital cap\u003c\/td\u003e\n\u003ctd\u003e~6.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLife-science cap\u003c\/td\u003e\n\u003ctd\u003e~5.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUM\u003c\/td\u003e\n\u003ctd\u003e~$3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaturing debt\u003c\/td\u003e\n\u003ctd\u003e~$420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMPT PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact MPT PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the content, layout, and insights visible in the preview are identical to the file you’ll download immediately after payment.\u003c\/p\u003e\n\u003cp\u003eEverything displayed is part of the final product, so what you see here is exactly what you’ll be working with.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751913402745,"sku":"medicalpropertiestrust-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/medicalpropertiestrust-pestle-analysis.png?v=1772236029","url":"https:\/\/matrixbcg.com\/products\/medicalpropertiestrust-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}